Avastin may benefit glaucoma patients

Article

Intravitreal bevacizumab (Avastin) may be an important additional treatment option for the rapid resolution of neovascular glaucoma (NVG), according to the results of a study conducted by Maia Kalev-Landoy and colleagues from the Wolfson Medical Center, Israel.

Intravitreal bevacizumab (Avastin) may be an important additional treatment option for the rapid resolution of neovascular glaucoma (NVG), according to the results of a study conducted by Maia Kalev-Landoy and colleagues from the Wolfson Medical Center, Israel.

Four eyes of four patients with NVG were treated with intravitreal bevacizumab. In two eyes, NVG was secondary to proliferative diabetic retinopathy (PDR) and the other two were secondary to central retinal vein occlusion (CRVO) and central retinal artery occlusion (CRAO), respectively. Each patient received a single 1.25 mg injection of bevacizumab. In addition to anti-glaucoma treatment, two patients received full panretinal photocoagulation (PRP).

All patients demonstrated a rapid progression of iris and angle neovascularization, with normalization of intraocular pressure (IOP). Mean IOP prior to treatment was 52.5 mmHg and this reduced to a mean of 16.2 mmHg post-treatment. Mean time from injection to regression of the neovascularization and normalization of IOP was four days.

The results suggest that intravitreal bevacizumab could be a useful treatment option for the rapid resolution of NVG.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.